Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial
暂无分享,去创建一个
C. Cooper | N. Arden | M. Javaid | A. Judge | D. Prieto-Alhambra | K. Lyles | C. Cooper | Muhammad Javaid | Muhammad Javaid | Nigel K. Arden | Andrew Judge | Kenneth W. Lyles
[1] L. Lix,et al. Competing mortality and fracture risk assessment , 2013, Osteoporosis International.
[2] Gordon H Guyatt,et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review , 2012, BMJ : British Medical Journal.
[3] A. Oxman. Subgroup analyses , 2012, BMJ : British Medical Journal.
[4] L. Fratiglioni,et al. Undertreatment of osteoporosis in persons with dementia? A population-based study , 2012, Osteoporosis International.
[5] C. Cooper,et al. Osteoporosis: burden, health care provision and opportunities in the EU , 2011, Archives of osteoporosis.
[6] S. Boonen,et al. Coordinator-based systems for secondary prevention in fragility fracture patients , 2011, Osteoporosis International.
[7] C. Moran,et al. Nottingham Hip Fracture Score as a predictor of one year mortality in patients undergoing surgical repair of fractured neck of femur. , 2011, British journal of anaesthesia.
[8] M. Safford,et al. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. , 2010, Journal of the American Medical Directors Association.
[9] Douglas P Kiel,et al. Competing Risk of Death: An Important Consideration in Studies of Older Adults , 2010, Journal of the American Geriatrics Society.
[10] Xin Sun,et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses , 2010, BMJ : British Medical Journal.
[11] M. Tinetti,et al. The patient who falls: "It's always a trade-off". , 2010, JAMA.
[12] S. Boonen,et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] Emma Smith,et al. Recurrent and injurious falls in the year following hip fracture: a prospective study of incidence and risk factors from the Sarcopenia and Hip Fracture study. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.
[14] C. Moran,et al. Development and validation of a preoperative scoring system to predict 30 day mortality in patients undergoing hip fracture surgery. , 2008, British journal of anaesthesia.
[15] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[16] J. Hirdes,et al. Factors associated with pharmacologic treatment of osteoporosis in an older home care population. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.
[17] I. Mühlhauser,et al. Risedronate for the prevention of hip fractures: concern about validity of trials. , 2007, Archives of internal medicine.
[18] D. Marsh,et al. Outcome Following Proximal Femoral Fracture in Northern Ireland , 2006, The Ulster medical journal.
[19] J. Iwamoto,et al. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. , 2005, Archives of internal medicine.
[20] Douglas G Altman,et al. Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.
[21] K. Carriere,et al. Functional Dependence After Hip Fracture , 2001, American journal of physical medicine & rehabilitation.
[22] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[23] A. Lusky,et al. Cognitive status at admission: does it affect the rehabilitation outcome of elderly patients with hip fracture? , 1999, Archives of physical medicine and rehabilitation.
[24] J. Mucklow,et al. Studies of the oral bioavailability of alendronate , 1995, Clinical pharmacology and therapeutics.
[25] A. Galecki,et al. Identifying elderly patients for early discharge after hospitalization for hip fracture. , 1993, Journal of gerontology.
[26] D. Wood,et al. Factors which influence mortality after subcapital hip fracture. , 1992, The Journal of bone and joint surgery. British volume.
[27] R. Sulkava,et al. Short Portable Mental Status Questionnaire as a Screening Test for Dementia and Delirium Among the Elderly , 1987, Journal of the American Geriatrics Society.
[28] D. Elmqvist,et al. Cardiovascular and neurological function in elderly patients sustaining a fracture of the neck of the femur. , 1981, The Journal of bone and joint surgery. British volume.
[29] D. Prudham,et al. A prospective study of fractured proximal femur: factors predisposing to survival. , 1979, Age and ageing.
[30] E. Pfeiffer. A Short Portable Mental Status Questionnaire for the Assessment of Organic Brain Deficit in Elderly Patients † , 1975, Journal of the American Geriatrics Society.
[31] J. Ide,et al. Prediction of postoperative ambulatory status 1 year after hip fracture surgery. , 2010, Archives of physical medicine and rehabilitation.
[32] S. Berney,et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis , 2008 .